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Abstract
Interstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks
after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C.
Herein, we present a 68-year-old man with chronic hepatitis C virus infection who developed
interstitial pneumonitis association with pegylated interferon after 36 weeks initiation of pegylated
interferon-alpha and ribavirin therapy. He did not recover after discontinuation of pegylated
interferon/ribavirin and improved by steroid therapy.
Introduction
Chronic hepatitis C virus (HCV) infection is recognized as
a global health problem with approximately 200 million
people estimated to be infected worldwide. The treatment
for chronic HCV infection has evolved over the last decade
from standard interferon (IFN) monotherapy to combina-
tion therapy with standard IFN and ribavirin and more
recently, pegylated (PEG) IFN and ribavirin combination
therapy [1,2].
Common side effects of IFN include fatigue, flu-like
symptoms, headache, arthralgia, myalgia, gastrointestinal,
and neuropsychiatric symptoms. Rare serious adverse
effects of IFN treatment are cardiac arrhythmias,
cardiomyopathy, hearing loss, pancreatitis and pulmonary
toxicity [3–6].
Reported pulmonary complications include interstitial
pneumonitis, pulmonary sarcoidosis, pleural effusion,
exacerbation of bronchial asthma and bronchiolitis
obliterans organizing pneumonia [6].
Ribavirin is generally well tolerated; the major side effects
of ribavirin are dose-dependent hemolytic anemia, cough,
dyspnea, rash, depression, and dyspepsia. No cases of
interstitial pneumonitis caused by ribavirin alone have yet
been described to this date. We describe here a case of who
developed interstitial pneumonitis following once weekly
dose of PEG IFN-alpha in combination with ribavirin
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initiation of combination treatment and discussed the
literature.
Case presentation
A 68-year-old healthy man was evaluated in the ambula-
tory care facility for elevated liver enzymes. He was found
to be asymptomatic and physical examination was
unremarkable. Laboratory tests revealed an aspartate
aminotransferase (AST) level of 72 U/L (normal up to 41
U/L), alanine aminotransferase (ALT) level of 89 U/L
(normal up to 41 U/L), and positive serology for HCV.
Serum electrolytes, complete blood count, and prothrom-
bin time were normal. The HCV RNA titer by polymerase
chain reaction was 200,000 copies/ml and genotype was
1b. Liver biopsy prior to PEG IFN a-2a/ribavirin therapy
was denied by the patient. Due to persistent elevated ALT
and AST for 6 months, therapy was started with 100 μgo f
PEG IFN a-2a subcutaneously per week in combination
with 800 mg ribavirin orally per day for chronic HCV
infection. The patient responded well, his aminotransfer-
ase levels normalized, and HCV RNA was undetectable at
week 12. The patient was continued combination therapy.
However, after 36 weeks of treatment, he presented with
exertional dyspnea. Although full interferon dose was
reinstituted, the dose of ribavirin was lowered to 600 mg/
day because of anemia (Hb: 10.6 g/dl). Dyspnea
progressed mild to moderate although the ribavirin dose
was decreased.
Physical examination was remarkable for bilateral crackles
at the lung bases. The patient was further treated with
furosemide for presumed congestive heart failure but
failed to improve. No third heart sound was audible, and
there was no jugular venous distension, hepatojugular
reflux, or other evidence of congestive heart failure.
Echocardiography revealed normal left ventricular func-
tion. A chest x-ray performed before therapy was
unremarkable. New chest x-ray and high-resolution
computed tomography (HRCT) of the lung revealed
bilateral interstitial infiltrates, predominantly in the lung
bases and periphery with subpleural parenchymal bands
and ground-glass opacities that were greater on the right
than on the left consistent with interstitial pneumonitis
(Figure 1). Pulmonary function tests (PFTs) revealed a
restrictive defect and a diminished diffusing capacity. The
forced expiratory volume in 1 second (FEV1) was 2.36 L
(60% of predicted reference), the forced vital capacity
(FVC) was 2.65 L (55% of predicted reference), and the
FEV1/FVC percentage ratio was 89%. Diffusing lung
capacity (DLCO) was 85% of predicted reference. Oxyhe-
moglobin saturation dropped to 87% while on breathing
room air and the patient was consequently given oxygen
therapy using a nasal cannula.
Interstitial pneumonitis secondary to PEG IFN a-2a and
ribavirin was suspected. PEG IFN a-2a and ribavirin were
discontinued at 36 weeks. HCV RNA by PCR was
undetectable. One month after the discontinuation of
treatment, symptomatic improvement was not noted.
Therapy with 32 mg of methylprednisolone orally once
per day was started by the consulting pulmonologist since
mild exertional dyspnea and mild hypoxemia persisted.
The steroid dose was gradually tapered over the next
several months and 4 mg/day methylprednisolone con-
tinued. Repeat PFTs showed marked improvement in his
lung volumes and air flow.
Two months after cessation of therapy and with steroid
treatment, a chest CT scan was repeated and compared to
the previous CT scan. It showed marked improvement of
the CT scan abnormalities but not complete resolution
(Figure 2). Eleven months after the diagnosis of interstitial
pneumonitis, steroid maintenance therapy was stopped by
the consulting pulmonologist since the patient became
asymptomatic with significant improvement in his chest
CT scans (Figure 3).
Figure 1
High-resolution computed tomography of the chest (HRCT)
demonstrates bilateral interstitial infiltrates, predominantly in
the lung bases and periphery with subpleural parenchymal
bands and ground-glass opacities that were greater on the
right than on the left consistent with interstitial pneumonitis.
Figure 2
Repeat HRCT of patient performed after two months
discontinuation of PEG-IFN and ribavirin with systemic steroid
therapy, showing improvement of the ground glass opacities.
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of steroid therapy and increased to 4 x 10
6 copy/ml one
year after cessation of PEG IFN a-2a and ribavirin therapy.
Discussion
Interstitial pneumonitis during PEG IFN alpha+ribavirin
therapy for chronic hepatitis C patients is generally
thought to be an unusual pulmonary side effect. There
have been only 6 cases reported as a complication of the
therapy with PEG-IFN alpha plus ribavirin for chronic
HCV infection in the English literature [7–11]. Three of
them died due to progressive hypoxemia and multisystem
organ failure. These patients’ death should be considered a
drug-related mortality. To the best our knowledge, whilst
the present case has been the 6th case of who developed
interstitial pneumonitis during PEG IFN alpha+ribavirin
therapy for chronic HCV infection, he has been third case
as survived. Although in previously described 5 cases,
interstitial pneumonitis usually developed from 2 weeks
to 16 weeks after starting PEG IFN alpha/ribavirin therapy
for HCV infection, our patient has also been the first case
of who developed interstitial pneumonitis after 36 weeks
of the treatment with PEG IFN alpha+ribavirin for chronic
HCV infection in the literature. It suggested that interstitial
pneumonitis can also develop at any time which either
early or late during combination therapy with PEG IFN-
alpha and ribavirin for chronic HCV infection.
In this patient, it seems highly likely that PEG IFN
treatment was responsible for the onset of interstitial
pneumonitis since all other possible infectious or systemic
causes were ruled out, there existed a temporal relation-
ship between the peg-interferon treatment and the onsetof
interstitial pneumonitis, the absence of any previous
pulmonary history, and the specificity of the results of
the various investigations carried out in the context of the
interstitial pneumonitis. We used the Naranjo algorithm
to show the probability of adverse drug reaction [12].
Interferon toxicity is generally dose dependent and
increases with increasing dose and duration of treatment,
although no clear relationship between dose and like-
lihood of side effects has been demonstrated [13]. PEG
IFN provides higher levels of interferon because of longer
absorption and prolonged half-life. Although the toler-
ability of PEG IFN alpha is comparable to that of
conventional IFN alpha, pulmonary toxicity may occur
more frequently with long-acting PEG IFN alpha therapy.
A potential role of ribavirin in pulmonary side effects
during combination therapy with PEG IFN remains
speculative. Ribavirin’s known adverse symptoms of
dyspnea and cough may suggest the possibility of
independent pulmonary toxicity [14]. However, pulmon-
ary side effects such as cough and dyspnea are common
side effects and may make detection of interferon-related
lung disease more difficult.
Ribavirin alone has never been reported as the cause for
interstitial pneumonitis to this date; however, the rates of
pulmonary toxicity with combination interferon/ribavirin
seem no higher than with interferon alone. IFN-alpha
seems to be the main agent for interstitial pneumonitis.
Although the pathogenesis associated with PEG IFN is not
well known, two possible mechanisms have been put
forward to explain drug-induced interstitial pneumonitis,
one of which is the direct toxicity of the drug to the
pulmonary organ, and the other is an indirect mechanism
acting via immunological pathways. Most cases of inter-
feron-associated pulmonary toxicity in patients with
chronic hepatitis C reported in the literature were
reversible, in many instances simply by discontinuation
of therapy. Although some cases may respond well to
discontinuation of interferon therapy, with or without
corticosteroids, pulmonary involvement may not always
be responsive [15]. There are only four reports of sustained
interstitial pneumonitis despite withdrawal of IFN alpha /
ribavirin and subsequent immunosuppressive therapy
[8, 9, 11, 15]. In fact, our patient has required low-dose
steroid without complete resolution of CT scan abnorm-
alities consistent with interstitial pneumonitis almost
1 year after cessation of combination therapy.
Conclusion
This case described here suggests that the onset of
disabling dyspnea in any time during PEG IFN-alpha
and ribavirin therapy for chronic HCV infection should
not be taken to be simply a pulmonary side effect of
ribavirin. In clinical practice, the persistence of dyspnea
after ribavirin dose adaptation should incite the physician
to perform a pulmonary CT scan. Interstitial pneumonitis
should be considered in the differential diagnosis and
therapy must be withheld.
Figure 3
Repeat HRCT of patient performed after eleven months
discontinuation of PEG-IFN and ribavirin with systemic steroid
showing resolution (improvement) of the ground glass
opacities.
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